Answers are grounded in this paper and cite their sources.
Observational results show high patient satisfaction and significant improvements in psoriatic arthritis outcomes after treatment with guselkumab or IL-17 inhibitors.
Background/Aims Increased patient treatment satisfaction may improve therapeutic adherence and long-term outcomes. The efficacy of targeted drugs in psoriatic arthritis (PsA), including clinical and patient-reported outcomes (PROs), has been demonstrated in randomised controlled trials; however, real-world data are scarcer, particularly for IL-23 and IL-17 inhibitors (i). This analysis aimed to assess PsA PROs and patient satisfaction with guselkumab (GUS) and IL-17i treatment at 12 months. Methods PsABIOnd (NCT05049798) is an ongoing, global, observational, study in PsA patients starting GUS or IL17i as 1st to-4th line of biologic therapy per standard of care.1 In this interim analysis, PsABIOnd participants with a baseline and ≥1 follow-up assessment through the 12-month visit (+/ 3 months) were analysed according to their initial treatment, regardless of later switches. Patient-reported impact was assessed with the PsA Impact of Disease-12 (PsAID12; 0-10) questionnaire and patient global assessment of PsA activity (PtGA; 0-100 VAS). Mean changes from baseline to 12 months in PsAID-12 total score and PtGA, and proportions of participants achieving PsAID-12 minimal clinically important improvement (MCII; improvement ≥1.4) were determined. Patient satisfaction with treatment was descriptively assessed with mean scores (0-100; higher being better) in effectiveness, convenience, and global satisfaction domains of the Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9)2 and with proportions of participants rating their well-being as improved and symptoms as acceptable using the Patient Acceptable Symptom State (PASS) scale.3 No statistical comparisons were performed. Results A total of 511 and 504 participants received GUS or IL-17i, respectively, as initial treatment. Sex (60.7%/59.7% female), prior targeted drug use (62.6%/62.9%), and mean age (53.0/53.7 years), PsAID-12 total score (5.1/5.1), and PtGA (59.4/60.7) were comparable for GUS/IL-17i at baseline. At the 12-month visit, mean changes from baseline in PsAID-12 total score (-1.6/-1.7) and in PtGA (-17.0/- 19.1), and rates of participants achieving PsAID-12 MCII (56.8%/53.7%) were similar with GUS and IL-17i. Patient satisfaction with GUS vs IL-17i at the 12-month visit was high, with similar proportions of participants rating their overall well-being as better (57.7%/64.9%) and in an acceptable state (61.0%/64.2%), and comparable mean TSQM-9 scores across domains (61.8/63.8). Conclusion By 12 months of treatment, clinically meaningful improvements in multidomain PROs and high levels of satisfaction were seen in participants treated in real-world with GUS or IL-17i, with the majority reporting achievement of acceptable state. These results may aid shared treatment decision-making by facilitating discussions on patient expectations.References:1. Siebert S, et al. Rheumatol Ther. 2023;10(2):489-5052. Atkinson MJ, et al. Health Qual Life Outcomes. 2004;2:123. Tubach F, et al. Arthritis Rheum. 2006;55(6):960-3 Disclosure L. Gossec: Consultancies; AbbVie, AlfaSigma, Amgen, Bristol Myers Squibb, Celltrion, Johnson & Johnson, Eli Lilly, MSD, Novartis, Pfizer, Stada, UCB. Honoraria; AbbVie, AlfaSigma, Amgen, Bristol Myers Squibb, Celltrion, Johnson & Johnson, Eli Lilly, MSD, Novartis, Pfizer, Stada, UCB. Grants/research support; AbbVie, Biogen, Eli Lilly, Novartis, UCB. M. Sharaf: Corporate appointments; Johnson & Johnson. Shareholder/stock ownership; Johnson & Johnson. X. Baraliakos: Consultancies; Abbvie, Chugai, Eli Lilly, Johnson & Johnson, MSD, Novartis, Pfizer, Roche, UCB. Honoraria; Abbvie, Chugai, Eli Lilly, Johnson & Johnson, MSD, Novartis, Pfizer, Roche, UCB. Member of speakers’ bureau; AbbVie, Chugai, Eli Lilly, Johnson & Johnson, MSD, Novartis, Pfizer, Roche, UCB. Grants/research support; AbbVie, Eli Lilly, Johnson & Johnson, MSD, Novartis. M. Kishimoto: Consultancies; Abbvie, Amgen, Asahi-Kasei Pharma, Astellas, Ayumi, Bristol Myers Squibb, Chugai, Daichii-Sankyo, Eisai, Eli Lilly, Gilead, Johnson & Johnson, Novartis, Tanabe-Mitsubishi, UCB. Honoraria; Abbvie, Amgen, Asahi-Kasei Pharma, Astellas, Ayumi, Bristol Myers Squibb, Chugai, Daichii-Sankyo, Eisai, Eli Lilly, Gilead, Johnson & Johnson, Novartis, Tanabe-Mitsubishi, UCB. R. Queiro: Consultancies; Abbvie, Amgen, Celgene, Johnson & Johnson, Eli Lilly, MSD, Novartis, Pfizer. Honoraria; Abbvie, Amgen, Celgene, Johnson & Johnson, Eli Lilly, MSD, Novartis, Pfizer. Grants/research support; Abbvie, Johnson & Johnson, Novartis. E. Lubrano: Honoraria; Abbvie, Amgen, Eli Lilly, GSK, Johnson & Johnson, Novartis, UCB. E. Rampakakis: Corporate appointments; JSS Medical Research. Consultancies; Johnson & Johnson. L. Köleséri: Corporate appointments; IQVIA. Consultancies; Johnson & Johnson. K. Lozenski: Corporate appointments; Johnson & Johnson. Shareholder/stock ownership; Johnson & Johnson, Bristol Myers Squibb. C. Roux: Consultancies; Galapagos. E. Soriano: Consultancies; Abbvie, Johnson & Johnson, Novartis, Roche. Honoraria; Abbvie, Johnson & Johnson, Novartis, Roche. Member of speakers’ bureau; Abbvie, Amgen, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, Roche, UCB. Grants/research support; AbbVie, Johnson & Johnson, Novartis, Pfizer, Roche, UCB. P. Rahman: Consultancies; Abbvie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, UCB. Honoraria; Abbvie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, UCB. Grants/research support; Johnson & Johnson, Novartis. Other; Meeting attendance/travel support: Johnson & Johnson. F. Behrens: Consultancies; AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, Eli Lilly, Galapagos, Genzyme, Gilead, Johnson & Johnson, MSD, Novartis, Pfizer, Roche, Sanofi, UCB. Honoraria; AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, Eli Lilly, Galapagos, Genzyme, Gilead, Johnson & Johnson, MSD, Novartis, Pfizer, Roche, Sanofi, UCB. Grants/research support; Celgene, Chugai, Johnson & Johnson, Pfizer, Roche. S. Siebert: Consultancies; AbbVie, Amgen, AstraZeneca, Johnson & Johnson, Syncona, Teijin Pharma, UCB. Honoraria; AbbVie, Amgen, AstraZeneca, Johnson & Johnson, Syncona, Teijin Pharma, UCB. Member of speakers’ bureau; AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer, UCB. Grants/research support; Eli Lilly, GSK, Johnson & Johnson, Pfizer, UCB.
No takes yet. Share an insight, caveat, or question.
Gossec et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: